Cardiotoxicity of cancer chemotherapy¿Recent developments

• Type: Chapter or Part of a Book
• Date: 2016

Authors

Adão, R (Author) Other; Maia Rocha, C (Author) Other; Santos Ribeiro, D (Author) Other; Mendes Ferreira, P (Author) Other; Leite-Moreira AF (Author) FMUP; Brás-Silva C (Author) FCNAUP

Book

Title: Frontiers in Drug Design & Discovery

Pages: 36-83

ISBN: 9781681081656

Indexing

Scopus - 1 Citation

Other information

Authenticus ID: P-00M-8C9

DOI: 10.2174/9781681081656116070004

Abstract (EN): The extensive use of chemotherapy in clinical practice has led to considerable controversy due to their potential adverse cardiovascular effects in surviving cancer patients. Among the effects of chemotherapeutic agents on the cardiovascular system, the most frequent and serious is heart failure with ventricular systolic dysfunction. Other harmful effects include hypertension, thromboembolic disease, pericardial disease, arrhythmias and myocardial ischemia. Cancer therapy-induced cardiomyopathy was almost exclusively associated with the use of cumulative doses of anthracyclines. However, new therapeutic agents, such as the monoclonal antibody trastuzumab, induce transient reversible myocyte dysfunction. Recent research to limit cardiotoxicity has focused on early monitoring and risk stratification to identify patients that are `at risk¿ for cardiotoxicity, using biochemical markers and the prophylactic use of novel cardioprotective agents. This chapter reviews the clinical course, pathogenesis, cardiac monitoring and new concepts in diagnosing and preventing chemotherapy cardiotoxicity.

Language: English

Type (Professor's evaluation): Scientific